Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
bluebird bio Analyst Ratings and Price Targets | NASDAQ:BLUE | Benzinga
bluebird bio Inc has a consensus price target of $7.68 based on the ratings of 15 analysts. The high is $40 issued by Barclays on December 31, 2024. The low is $0.5 issued by B of A Securities on November 15, 2024. The 3 most-recent analyst ratings were released by Wells Fargo, Barclays, and RBC Capital on February 24, 2025, December 31, 2024, and November 15, 2024, respectively. With an average price target of $16.33 between Wells Fargo, Barclays, and RBC Capital, there's an implied 327.02% upside for bluebird bio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Barclays
RBC Capital
B of A Securities
Baird
1calculated from analyst ratings
Analyst Ratings for bluebird bio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/24/2025 | Buy Now | 30.72% | Wells Fargo | Yanan Zhu35% | $40 → $5 | Maintains | Equal-Weight | Get Alert |
| 02/24/2025 | Buy Now | — | JP Morgan | Eric Joseph47% | — | Upgrade | Underweight → Neutral | Get Alert |
| 12/31/2024 | Buy Now | 945.75% | Barclays | Gena Wang51% | $2 → $40 | Maintains | Overweight | Get Alert |
| 11/15/2024 | Buy Now | 4.58% | RBC Capital | Luca Issi42% | $80 → $80 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 11/15/2024 | Buy Now | -86.93% | B of A Securities | Jason Gerberry63% | $60 → $10 | Downgrade | Buy → Neutral | Get Alert |
| 11/15/2024 | Buy Now | -47.71% | Barclays | Gena Wang51% | $80 → $40 | Maintains | Overweight | Get Alert |
| 09/25/2024 | Buy Now | -47.71% | Wells Fargo | Yanan Zhu35% | $60 → $40 | Maintains | Equal-Weight | Get Alert |
| 09/16/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt31% | — | Reiterates | → Neutral | Get Alert |
| 08/15/2024 | Buy Now | -21.57% | B of A Securities | Jason Gerberry63% | $80 → $60 | Maintains | Buy | Get Alert |
| 08/15/2024 | Buy Now | 4.58% | RBC Capital | Luca Issi42% | $80 → $80 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/15/2024 | Buy Now | 4.58% | Barclays | Gena Wang51% | $160 → $80 | Maintains | Overweight | Get Alert |
| 08/15/2024 | Buy Now | 56.86% | Baird | Jack Allen 36% | $140 → $120 | Maintains | Outperform | Get Alert |
| 08/15/2024 | Buy Now | — | JP Morgan | Eric Joseph47% | — | Downgrade | Overweight → Neutral | Get Alert |
| 03/27/2024 | Buy Now | 56.86% | RBC Capital | Luca Issi42% | $120 → $160 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/27/2024 | Buy Now | -21.57% | Wells Fargo | Yanan Zhu35% | $80 → $60 | Maintains | Equal-Weight | Get Alert |
| 03/19/2024 | Buy Now | -56.08% | Wedbush | David Nierengarten63% | $60 → $33.6 | Maintains | Neutral | Get Alert |
| 03/05/2024 | Buy Now | -73.33% | HSBC | Morten Herholdt40% | $46.2 → $20.4 | Maintains | Reduce | Get Alert |
| 12/21/2023 | Buy Now | 30.72% | B of A Securities | Jason Gerberry63% | $240 → $100 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | 30.72% | Wells Fargo | Yanan Zhu35% | $160 → $100 | Maintains | Equal-Weight | Get Alert |
| 12/12/2023 | Buy Now | 83.01% | Baird | Jack Allen 36% | $200 → $140 | Maintains | Outperform | Get Alert |
| 12/11/2023 | Buy Now | 213.73% | B of A Securities | Jason Gerberry63% | $220 → $240 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | 83.01% | Morgan Stanley | Jeffrey Hung55% | $60 → $140 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/08/2023 | Buy Now | 239.87% | Raymond James | Dane Leone45% | $200 → $260 | Maintains | Outperform | Get Alert |
| 10/17/2023 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt31% | — | Initiates | → Neutral | Get Alert |
| 09/06/2023 | Buy Now | 10.07% | HSBC | Morten Herholdt40% | → $84.2 | Initiates | → Buy | Get Alert |
| 07/19/2023 | Buy Now | 161.44% | B of A Securities | Jason Gerberry63% | $120 → $200 | Upgrade | Neutral → Buy | Get Alert |
| 07/11/2023 | Buy Now | -21.57% | Morgan Stanley | Matthew Harrison60% | $60 → $60 | Reiterates | Underweight → Underweight | Get Alert |
| 06/01/2023 | Buy Now | 109.15% | Barclays | Gena Wang51% | $140 → $160 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/28/2023 | Buy Now | 83.01% | JP Morgan | Eric Joseph47% | → $140 | Initiates | → Overweight | Get Alert |
| 04/03/2023 | Buy Now | -21.57% | Morgan Stanley | Matthew Harrison60% | $80 → $60 | Maintains | Underweight | Get Alert |
| 03/30/2023 | Buy Now | 109.15% | RBC Capital | Luca Issi42% | → $160 | Reiterates | → Sector Perform | Get Alert |
| 03/30/2023 | Buy Now | 56.86% | B of A Securities | Jason Gerberry63% | $160 → $120 | Maintains | Neutral | Get Alert |
| 03/07/2023 | Buy Now | 161.44% | Baird | Jack Allen 36% | → $200 | Initiates | → Outperform | Get Alert |
| 01/24/2023 | Buy Now | 4.58% | Morgan Stanley | Matthew Harrison60% | $60 → $80 | Maintains | Underweight | Get Alert |
| 01/23/2023 | Buy Now | 109.15% | SVB Leerink | Mani Foroohar45% | $180 → $160 | Maintains | Market Perform | Get Alert |
| 01/06/2023 | Buy Now | 135.29% | SVB Leerink | Mani Foroohar45% | $160 → $180 | Maintains | Market Perform | Get Alert |
| 11/08/2022 | Buy Now | 109.15% | RBC Capital | Luca Issi42% | $2000 → $160 | Maintains | Sector Perform | Get Alert |
| 09/20/2022 | Buy Now | 161.44% | Raymond James | Dane Leone45% | $160 → $200 | Maintains | Outperform | Get Alert |
| 08/19/2022 | Buy Now | -21.57% | Goldman Sachs | Salveen Richter53% | $40 → $60 | Maintains | Sell | Get Alert |
| 08/18/2022 | Buy Now | 161.44% | SVB Leerink | Mani Foroohar45% | $160 → $200 | Maintains | Market Perform | Get Alert |
| 08/05/2022 | Buy Now | 30.72% | Barclays | Gena Wang51% | $60 → $100 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 08/02/2022 | Buy Now | 109.15% | Raymond James | Dane Leone45% | → $160 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/24/2022 | Buy Now | -47.71% | Goldman Sachs | Salveen Richter53% | $60 → $40 | Maintains | Sell | Get Alert |
| 05/17/2022 | Buy Now | -21.57% | Morgan Stanley | Matthew Harrison60% | $100 → $60 | Maintains | Underweight | Get Alert |
| 05/10/2022 | Buy Now | -21.57% | Barclays | Gena Wang51% | $80 → $60 | Maintains | Underweight | Get Alert |
| 04/06/2022 | Buy Now | — | Cowen & Co. | Yaron Werber35% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 04/06/2022 | Buy Now | 109.15% | SVB Leerink | Mani Foroohar45% | $200 → $160 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for bluebird bio (BLUE) stock?
The latest price target for bluebird bio (NASDAQ:BLUE) was reported by Wells Fargo on February 24, 2025. The analyst firm set a price target for $5.00 expecting BLUE to rise to within 12 months (a possible 30.72% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for bluebird bio (BLUE)?
The latest analyst rating for bluebird bio (NASDAQ:BLUE) was provided by Wells Fargo, and bluebird bio maintained their equal-weight rating.
When was the last upgrade for bluebird bio (BLUE)?
The last upgrade for bluebird bio Inc happened on February 24, 2025 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for bluebird bio Inc.
When was the last downgrade for bluebird bio (BLUE)?
The last downgrade for bluebird bio Inc happened on November 15, 2024 when B of A Securities changed their price target from $3 to $0.5 for bluebird bio Inc.
When is the next analyst rating going to be posted or updated for bluebird bio (BLUE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of bluebird bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for bluebird bio was filed on February 24, 2025 so you should expect the next rating to be made available sometime around February 24, 2026.
Is the Analyst Rating bluebird bio (BLUE) correct?
While ratings are subjective and will change, the latest bluebird bio (BLUE) rating was a maintained with a price target of $40.00 to $5.00. The current price bluebird bio (BLUE) is trading at is $3.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.